Lakefront Biotherapeutics NV (LKFT) revenue breakdown
By segment, Research and Development Segment is the largest at 99% of fiscal 2019 revenue, growing 90% a year over 3 years.
By region, United States is the largest at 99% of fiscal 2020 revenue, growing 52% a year over 4 years.
Revenue by segment
Fiscal years, as Lakefront Biotherapeutics NV reports them in its 10-K filings; fiscal 2019 total $845M.
| Segments | 2016 | 2017 | 2018 | 2019 | Share |
|---|---|---|---|---|---|
| Research and Development Segment | $122M | $118M | $279M | $835M | 99% |
| Fee for services segment | $8M | $9M | $10M | $10M | 1% |
Revenue by region
Fiscal years, as Lakefront Biotherapeutics NV reports them in its 10-K filings; fiscal 2020 total $478M.
| Regions | 2016 | 2017 | 2018 | 2019 | 2020 | Share |
|---|---|---|---|---|---|---|
| United States | $89M | $82M | $117M | $794M | $472M | 99% |
| Europe | $41M | $45M | $162M | $41M | $6M | 1% |
| Asia Pacific | $6,000 | — | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for LKFT.
Open LKFT in InvestinglyQuestions
Where does Lakefront Biotherapeutics NV make its money?
In fiscal 2019, by segment: Research and Development Segment $835M, Fee for services segment $10M.
From Lakefront Biotherapeutics NV's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.